• COVID-19 Vaccine Additional Booster Dose Recommendations (March 30 2022)
• Updates to COVID-19 Laboratory Reporting Requirements (March 25 2022)
• FDA Recall on Powdered Infant Formula and Multistate Investigation of Cronobacter sakazakii Infections Associated with Powdered Infant Formula (March 1 2022)
• Updated Interim Clinical Considerations for COVID-19 Vaccine Use (Feb. 25 2022)
• FDA Recall on Powdered Infant Formula and Multistate Investigation of Cronobacter sakazakii Infections Associated with Powdered Infant Formula (Feb. 25 2022)
• New Vaccination Requirement for Nevada Public, Private, and Charter Schools (Feb. 23 2022)
• New Vaccination Requirement for Nevada Public, Private, and Charter Schools (Feb. 23 2022)
• 2021-22 Covid-19 Guidelines For Prevention And Outbreak Control In School Settings (Feb. 17 2022) 
• Mask Mitigation Requirements for Licensed Health Care Facilities (Feb. 10 2022).
• Updated Quarantine Guidance (Jan. 31 2022).
• Updated Quarantine Guidance (Jan. 18 2022).
• Developing and maintaining written plans that balance access to care, staffing shortages and infection control (Jan. 18 2022).
• COVID-19 Vaccine Updated Booster Dose Recommendations (Jan. 7 2022).

• Updated Antigen Testing (Dec. 30, 2021).
• At Home Test Kits Updated (Dec. 30, 2021)
• Updated Quarantine Guidance (Dec. 29, 2021).
• Updated Guidance for Discontinuation of COVID-19 Isolation (Dec. 29, 2021).
• Updated COVID-19, Influenza and RSV (Dev. 29, 2021).
• Boletín Técnico - Recomendaciones Preferentes para vacunas ARNm contra COVID-19 (Dic. 22, 2021).

• Boletín Técnico - Dosis de refuerzo de la vacuna Covid-19 para jóvenes de 16-17 años (Dec. 15, 2021)

• COVID-19 Vaccine Booster Dose Recommendations for Adults and Emergency Use Instructions (December 3, 2021)

• NV COVID-19 Playbook Brief - Booster Dose Eligibility (November 5, 2021)

• Clinical Considerations for Administering COVID-19 Pfizer-BioNTech Vaccine to Children Ages 5-11 Years (November 3, 2021)
• COVID Vaccine Booster Doses for Janssen/Johnson & Johnson (J&J) and Moderna (October 22. 2021)

• Clinical Laboratory Submission to State and Local Public Health Laboratories (October. 8 2021)

• Specimen Submissions to Public Health Laboratories (October. 8 2021)

• Update: COVID-19 Point of Care Antigen Testing in Community Settings (October. 1 2021)

• COVID-19, Influenza and RSV (September. 30 2021)
• Pfizer-BioNTech COVID-19 Vaccine Booster Recommendations (September.28, 2021)
• Quarantine new admits and readmissions regardless of vaccination status in nursing homes and residential facilities (September. 13,2021)
  
• Poner en cuarentena a los nuevos ingresos y a los reingresos, independientemente del estado de vacunacion en las residencias de ancianos e instalaciones residenciales. (September. 21, 2021)
• Updated Tuberculosis (TB) Testing Recommendations Around COVID-19 Vaccinations (September. 03, 2021)
• Recomendaciones actualizadas para las pruebas de tuberculosis (TB) en torno a las vacunas COVID-19 (September. 03, 2021)
• Regulatory Updates for COVID-19 Vaccines – U.S. Food and Drug Administration Approves Licensure of the Pfizer-BioNTech COVID-19 Vaccine (August. 25 2021)
• Actualizaciones Regulatorias para las Vacunas contra COVID-19– E.U. La Administración de Alimentos y Medicamentos Aprueba la licencia de la vacuna de Pfizer-BioNTech contra COVID-19 (August. 25 2021)
• Recommendations for COVID-19 Vaccination for People Who are Pregnant or Breastfeeding (August. 18, 2021)
• Recomendaciones para la vacuna contra COVID-19 para Personas Embarazadas o Mujeres bajo lactancia (August. 18, 2021)
• Additional mRNA COVID-19 Dose Recommended for Moderately and Severely Immunocompromised Individuals (August. 18, 2021)
• Dosis adicional de ARNm contra COVID-19 recomendada para individuos con inmunodepresión moderada o grave (August. 19, 2021)
• Sexually Transmitted Infections Treatment Guidelines, 2021 (August. 09, 2021)
• COVID-19 Data Reporting Requirement for Skilled Nursing Facilities (July. 26, 2021)
• Updated Tuberculosis (TB) Testing Interim Recommendations Around COVID-19 Vaccinations (July. 19, 2021)
• PrEP (Pre-Exposure Prophylaxis) and PEP (Post-Exposure Prophylaxis) (July. 12, 2021)
• Actualización de la secuenciación de COVID-19 - Los laboratorios clínicos deben enviar todas las muestras positivas de SARS-CoV-2 al laboratorio de slud pública del estado de Nevada (July. 02, 2021)
• Debates del ACIP sobre la miocarditis después de la vacunación con COVID-19 y la posible necesidad de dosis de refuerzo de COVID-19 (July. 02, 2021)
• ACIP Discussions on Myocarditis Post-COVID-19 Vaccination and Potential Need for COVID-19 Booster Doses (July. 02, 2021)
• Clinical Laboratories to Submit all Positive SARS-CoV-2 Samples to the Nevada State Public Health Laboratory (July. 02, 2021)
• Monitoring Reports of Myocarditis Post-COVID-19 Vaccination (June. 14, 2021)
• Public Health Considerations for COVID-19 At-Home Test Kits (June. 8, 2021)
  • Consideraciones de Salud Pública para los Kits de Prueba Casera para COVID-19 (June. 8, 2021)
• Clinical Considerations for Use of COVID-19 Vaccines (May. 27, 2021)
• Consideraciones Técnicas para el uso de las vacunas contra COVID-19 (May. 27, 2021)
• Expedited Partner Therapy (May. 24, 2021)
• Clinical considerations for administering Pfizer-BioNTech COVID-19 vaccine to adolescents ages 12-15 years (May. 18, 2021)
• All Skilled Nursing Facilities and Congregate Living Facilities (May. 17, 2021)
• Adverse Event Reporting Following COVID-19 Vaccination (May. 04, 2021)
  • Reportar Evento Adverso después de la recibir la Vacuna COVID-19
• Resuming Use of J&J COVID 19 Vaccine (May. 04, 2021)
  • A todo Profesional Médico e Instalaciones, Autoridades de Salud Locales, y Farmacéuticos
• Public Health Authorities, Health Care Providers and Long-Term Care Facilities (Apr. 28, 2021)
  • Autoridades de Salud Pública, Proveedores de Atención Médica y a Instalaciones de Cuidado de Largo Plazo (Apr. 28, 2021)
• Storage and Handling of COVID-19 Vaccines (Apr. 19, 2021)
• Ebola Virus Disease (Mar. 15, 2021)
• CDC Interim Public Health Recommendations for Fully Vaccinated Individuals (Mar. 10, 2021)
  • Recomendaciones Provisionales de Salud Pública para Personas Completamente Vacunadas de los CDC (Mar. 10, 2021)
• Implementation Considerations for the Janssen (Johnson & Johnson) COVID-19 Vaccine (Mar. 03, 2021)
  • Consideraciones de Implementación para la Vacuna contra COVID-19 de Janssen (Johnson & Johnson) COVID-19 (Mar. 03, 2021)
    
• Update to Nevada State Immunization Program Guidance on Vaccine Access for Nevadans with Underlying Health Conditions (Mar. 03, 2021)
  • Actualización a la Orientación del Programa de Inmunización del Estado de Nevada sobre Acceso a la Vacuna para las personas de Nevada con condiciones de salud subyacentes (Mar. 03, 2021)
• Quarantine Guidance for Vaccinated Persons (Mar. 03, 2021)
  • Orientación de Cuarentena para Personas Vacunadas (Mar. 03, 2021)
• Placement of patients/residents who have been vaccinated against COVID-19 or who have had COVID-19 and have recovered (Feb. 03, 2021)
  • Colocación de pacientes/ residentes que han sido vacunados contra COVID-19 o que han tenido COVID-19 y han recuperado (Feb. 03, 2021)
• Moderna Vaccine Lot 41L20A and higher incidence of adverse reactions (Feb. 03, 2021)
• Tuberculosis (TB) Testing Interim Recommendations Around COVID-19 Vaccinations (Jan. 15, 2021)
  • Recomendaciones Provisionales de la Prueba de Tuberculosis (TB) en relación con las vacunas contra COVID-19 (Jan. 15, 2021)

• COVID-19 Point of Care Antigen Testing (Dec. 18, 2020)
  • Novedad: Pruebas de Antígeno en el Punto de Atención para COVID-19 (Dec. 18, 2020)
• Requirement for Hospitals to Report Ban on Medically Necessary Procedures (Dec. 14, 2020)
  • Requisito para Hospitales Informar sobre la Prohibición de Procedimientos Medicamente Necesarios (Dec. 14, 2020)
• CDC Updated Guidance for Reducing Quarantine Period for Contacts of Persons with COVID-19 Infection (Dec. 2, 2020)
• Guidance for Discontinuation of COVID-19 Isolation (Nov. 19, 2020)
  • Orientación sobre la suspensión del aislamiento de COVID-19 (Nov. 19, 2020)
• REMOVAL OF DIRECTIVE to Discontinue the Use of Antigen Testing in Skilled Nursing Facilities Until Further Notice (Oct. 09, 2020)
• COVID-19 Laboratory Reporting Requirements (Sept. 04, 2020)
• COVID-19 Point of Care Testing (Aug. 28, 2020)
• Guidelines for Discontinuation of In-Home Isolation and Transmission-Based Precautions among Hospitalized Patients with COVID-19 (Jul. 23, 2020)
• Require Immediate Reporting of COVID-19 Test Results to the Nevada Division of Public and Behavioral Health (Jun. 24, 2020)
• Multisystem Inflammatory Syndrome in Children (MIS-C) and Required Reporting for MIS-C (Jun. 11, 2020)
  • Síndrome Inflamatorio Multisistémico en Niños (MIS-C) y Reportaje Requerido para MIS-C (Jun. 11, 2020)
• Pharmacists and Medical Laboratory Testing Under the PREP Act (Jun. 02, 2020)
  • Farmacéuticos y Prueba Médica de Laboratorio Bajo la Ley PREP (Jun. 02, 2020)
• Expansion of COVID-19 Testing Criteria (May 05, 2020)
  • Ampliación de los Criterios de Prueba para COVID-19 (May 05, 2020)
  • Laboratory Testing Frequently Asked Questions (May 05, 2020)
• Updated Testing Criteria for COVID-19 (Apr. 20, 2020)
• Non-Physician Practitioners and Home Health Orders (Apr. 17, 2020)
  • Practicantes No- Médicos y Órdenes de Atención Medica en el Hogar (Apr. 17, 2020)
• Interim Guidance on Alternative, Improvised and Homemade Facemasks (Apr. 04, 2020)
• Guidance for Health Care Personnel with Potential Exposure to COVID-19 Patients (Apr. 1, 2020)
• Visitors' Guide to Health Care Facilities (Mar. 30, 2020)
• COVID-19 Message to Employers (Mar. 27, 2020)
• Home Health Personnel and Coronavirus Disease 2019 (COVID-19) (Mar. 23, 2020)
• Updated Interim Testing Criteria for COVID-19 (Mar. 20, 2020)
• Interim Guidelines for Discontinuation of In-Home Isolation and Transmission-Based Precautions among Hospitalized Patients with COVID-19 (Mar. 17, 2020)
• COVID-19 Practices and Processes for Nevada Health Facilities (Mar. 16, 2020)
• Reporting of Extraordinary Occurrence of Illness (Mar. 05, 2020)
• CDC Updated Interim Infection Prevention & Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus in a Healthcare Setting (Jan. 31, 2020)
• Novel Coronavirus general information - issued 01-24-2020 (Jan. 24, 2020)

Other topics

• Radiation Control Programs
• Immunization Program
• Azithromycin Shortage and Alternative Sexually Transmitted Diseases (STD) Treatment (Dec. 18, 2020)
  • Escasez de Azitromicina y Tratamiento Alternativo para Enfermedades Transmitidas Sexualmente (STD por sus siglas en inglés) (Dec. 18, 2020)